CalciMedica, Inc. (CALC)
CalciMedica develops drug candidates that block CRAC channels to treat serious inflammatory and immune conditions. It last closed at $1.22 on Nov 17, up 2.52% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From CALC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on CALC in the past 90 days. The average target is $9.00, with a high of $9.00 and a low of $9.00, compared with the last close of $1.22.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | Guggenheim | Initiated | Buy | $9 |
Technical Analysis
The stock is 10% below its 20 day and 23% below its 50 day average. It is 142% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the Pivot S1 at $1.18, and the nearest resistance the Pivot at $1.23.
| RSI (14) | 42.89 | Middle of its range | Neutral |
| MACD | -0.07 | Below its signal line | Bearish |
| Stochastic | 8.6 | Near the bottom of its range | Oversold |
| ADX (14) | 21.1 | Weak trend | |
| Williams %R | -88.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -69.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −17.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.18 | Typical daily range, 14.8% of price |
| RSI (14) | 34.59 | Weak, oversold below 30 | Neutral |
| MACD | -1.25 | Above its signal line | Bullish |
| Stochastic | 8.9 | Near the bottom of its range | Oversold |
| ADX (14) | 14.7 | No clear trend | |
| Williams %R | -91.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -78.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −38.4% | Change over 10 sessions | Bearish |
| ATR (14) | $0.85 | Typical daily range, 69.3% of price |
What happened before
See how CALC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CALC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in CALC in the last 90 days.
CALC Institutional Ownership
Full report →- ▼17 buying vs 31 selling
- ▼Held by funds -97.0 pts
- ▼Funds holding -14
- ▼Superinvestors: 0 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 17 | 31 | −45.2% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 24.5% | 121.6% | −97.0 pts |
| New / increased | 17 / 0 | 10 / 5 | +13.3% |
| Reduced / sold out | 0 / 31 | 7 / 6 | +138.5% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CALC is in one of them and how their past CALC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CALC in an article yet. Here's the latest on the wider market.
About CalciMedica
CalciMedica is a biopharmaceutical company based in La Jolla, California, that develops drug candidates for serious illnesses involving inflammation and damage to tissue cells. Its drugs work by blocking CRAC channels, which play a role in immune and inflammatory signaling. Its lead candidate, Auxora, is an intravenous treatment that has been studied in acute care settings such as acute pancreatitis and kidney injury. The company is also researching the approach for other conditions, including pulmonary arterial hypertension. Its products are still in development and are not yet approved for sale, and they are intended for hospital and specialist use.
- Headquarters
- La Jolla, CA
